Search clinical trials for: GEJ cancer

Total 86685 results

Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
NeoImmuneTech
Bristol-Myers Squibb

Terminated

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)

United States, Poland
Daiichi Sankyo
AstraZeneca

Completed

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Adenocarcinoma Gastric Stage IV With Metastases | Adenocarcinoma - GEJ

United States, Spain, Belgium, Italy, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Akeso

Active, not recruiting

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Seagen Inc.

Terminated

A Study of SGN-STNV in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Colorectal Neoplasms | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Pseudomyxoma Peritonei | Carcinoma, Non-Small Cell Lung | Gastroesophageal Junction Carcinoma | HER2 Negative Breast Neoplasms | Exocrine Pancreatic Adenocarcinoma | Appendiceal...

United States, United Kingdom, Canada, Spain, France, Italy
Charles Drew University of Medicine and Science
National Institute on Minority Health and Health Disparities (NIMHD)

Completed

Cancer Leadership Training for Clergy Wives and Widows

Cancer | Patient Empowerment

United States
Hoffmann-La Roche

Terminated

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Stomach Neoplasms | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Mural Oncology, Inc

Completed

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Advanced Solid Tumors

Korea, Republic of, United States, Canada, Netherlands, Spain, Taiwan
Bristol-Myers Squibb

Completed

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Gastric Cancer | Esophagogastric Junction | Cancer of the Stomach

United States, Germany, Italy, Argentina, Australia, Belgium, France, Poland, Puerto Rico, Spain, Czechia, Austria, Canada, United Kingdom, Chile, Norway, Singapore
Krankenhaus Nordwest
German Research Foundation; Arbeitsgemeinschaft fur Internistische Onkologie

Active, not recruiting

Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5)

Gastric Cancer

Germany
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
Seagen Inc.

Terminated

A Study of SGN-ALPV in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Testicular Neoplasms | Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Gastroesophageal Junction Carcinoma

United States, Canada, Spain, Sweden, United Kingdom
University of Washington
Guerbet

Withdrawn

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

Malignant Neoplasm in the Head and Neck | Metastatic Malignant Neoplasm in the Head and Neck

United States
Zymeworks Inc.

Active, not recruiting

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

HER2-expressing Cancers

United States, Canada, Korea, Republic of, Australia
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Seagen Inc.

Active, not recruiting

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Korea, Republic of, United Kingdom, Taiwan, Canada, Australia
Vedanta Biosciences, Inc.
Bristol-Myers Squibb

Completed

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (ConsortiumIO)

Melanoma | Gastric Cancer | Colorectal Cancer | Metastatic Cancer | Gastroesophageal Junction Adenocarcinoma

United States
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
American College of Radiology Imaging Network
National Cancer Institute (NCI)

Active, not recruiting

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (ACRIN6690)

Liver Cancer

United States
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Vall d'Hebron Institute of Oncology

Active, not recruiting

Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (MONEO)

Stomach Neoplasms | Gastroesophageal Junction Adenocarcinoma

Spain
BeiGene

Completed

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Carcinoma, Hepatocellular | Gastric/Gastroesophageal Junction Cancer

China
Koning Corporation

Terminated

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Breast Cancer

United States
Incyte Corporation

Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Head and Neck Cancer | Gastric Cancer | Lung Cancer | Metastatic Cancer | Mesothelioma | Bladder Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer)

Italy, Spain, United States, Netherlands
Celularity Incorporated

Active, not recruiting

CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States
OncXerna Theraputics, Inc.
Merck Sharp & Dohme LLC

Completed

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

Gastric Cancer | GastroEsophageal Cancer

Korea, Republic of, United Kingdom, Taiwan, United States
Memorial Sloan Kettering Cancer Center

Terminated

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Gastric Cancer | Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Junction Cancer | Gastric Tumor | Gastroesophageal Junction Adenocarcinoma | GastroEsophageal Cancer | Esophageal Tumor | Esophagogastric Tumors | Gastroesophageal Junction Tumor

United States
Highlight Therapeutics

Terminated

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Gastric Cancer | Colorectal Cancer | Oesophageal Cancer

Spain, Belgium, Italy
InxMed (Shanghai) Co., Ltd.

Completed

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Gastric Cancer

China
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
AstraZeneca

Completed

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Neoplasm, Breast | Adenocarcinoma, Gastric

Taiwan
Akeso
Akeso Pharmaceuticals, Inc.

Active, not recruiting

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Gastric Adenocarcinoma | Advanced Solid Tumors | Gastroesophageal Junction Adenocarcinoma

China
Incyte Biosciences International Sàrl

Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Advanced Malignancies

United States
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
GB006, Inc., a wholly owned subsidiary of Gossamer...
Merck Sharp & Dohme LLC

Terminated

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal... and other conditions

United States, United Kingdom
Institut für Klinische Krebsforschung IKF GmbH...

Completed

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (RAMSES/FLOT7)

Stomach Cancer | Gastroesophageal Junction Cancer

Germany, Italy
Nanfang Hospital of Southern Medical University

Completed

Safety and Efficacy of OGT Method Versus the Traditional Overlap Method (OGT)

Gastric Cancer

China
Duke University

Completed

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers

Metastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Incyte Biosciences International Sàrl

Completed

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States, Belgium, Australia, Spain
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Solid Tumors

United States, Korea, Republic of, Taiwan, France, United Kingdom, Belgium, Czechia, Germany, Poland
Merck Sharp & Dohme LLC

Withdrawn

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Stomach Neoplasms

China
Incyte Biosciences International Sàrl

Terminated

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Gastric Cancer

China
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
Institut für Klinische Krebsforschung IKF GmbH...
Trium Analysis Online GmbH

Completed

FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (PETRARCA)

Stomach Cancer | Gastroesophageal Junction Cancer

Germany
University of Utah
Elevar Therapeutics

Terminated

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (APPEASE)

Urothelial Carcinoma | Advanced Malignancies | Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | MSI-H or dMMR Solid Tumors

United States
Eli Lilly and Company

Completed

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Poland, Romania, Hungary, Russian Federation, Australia, France, Argentina, United Kingdom, New Zealand, Turkey, Slovakia
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Completed

LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma

Esophageal Cancer

United States

Search clinical trials for: GEJ cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations